Description: This dataset provides decadal changes in total terrestrial water storage (TWS) across global endorheic basins, as observed by the Gravity Recovery and Climate Experiment (GRACE) satellites from April 2002 to March 2016. GRACE observations applied here are monthly equivalent water thickness (EWT) anomalies in the JPL 3-degree equal-area mason solution (JPL-RL05M version 2). Endorheic basin extents are acquired from the 15-second HydroSHEDS drainage basin dataset, with regional supplement of the Global Drainage Basin Database (GDBD). The global endorheic basins cover a total area of 33.7 million square kilometers, ranging from 52.8º S to 62.0º N and from 122.8º W to 157.6º E. TWS changes are calculated at two enumeration scales: 173 endorheic units and 10 endorheic zones (including Western North America, Dry Andes and Patagonia, Sahara and Arabia, Great Rift Valley and Southern Africa, Australia, Central Eurasia, and four secondary zones in Central Eurasia: the Caspian Sea Basin, the Aral Sea Basin, the Inner Tibetan Plateau, and Other Central Eurasia). At the unit scale, we provide 1) the trend of deseasonalized TWS anomalies from April 2002 to March 2016 and, 2) the trend uncertain (one standard deviation) propagated from the inherent errors in the original mascon data and the residuals of the best-fit linear trend fitting. At the zonal scale, we provide detailed monthly time series of 1) TWS anomalies (both original values and deseasonalized values) and 2) TWS uncertainties propagated from the inherent mason errors and rescaling uncertainties due to signal leakage in fringe mascons. Please see the source paper (Wang et al. 2018) for detailed data references, collections and processing.

Description: Background: The purpose of this study is to assess the predictive accuracy of a multi-gene predictor of response to docetaxel, 5-fluorouracil, epirubicin and cyclophosphamide combination chemotherapy on gene expression data from patients who received these drugs as neoadjuvant treatment. Methods: Tumor samples were obtained from patients with stage II-III breast cancer before starting neoadjuvant chemotherapy with four cycles of 5-fluorouracil/epirubicin/cyclophosphamide (FEC) followed by four cycles of docetaxel/capecitabine (TX) on US Oncology clinical trial 02-103. Most patients with HER-2-positive cancer also received trastuzumab (H). The chemotherapy predictor (TFEC-MGP) was developed from publicly available gene expression data of 42 breast cancer cell-lines with corresponding in vitro chemotherapy sensitivity results for the four chemotherapy drugs. No predictor was developed for treatment with trastuzumab. The predictive performance of TFEC-MGP in distinguishing cases with pathologic complete response from those with residual disease was evaluated for the FEC/TX and FEC/TX plus H group separately. The area under the receiver-operating characteristic curve (AU-ROC) was used as the metric of predictive performance. Genomic predictions were performed blinded to clinical outcome. Results: The AU-ROC was 0.70 (95 % CI: 0.57-0.82) for the FEC/TX group (n=66) and 0.43 (95 % CI: 0.20-0.66) for the FEC/TX plus H group (n=25). Among the patients treated with FEC/TX, the AU-ROC was 0.69 (95 % CI: 0.52-0.86) for estrogen receptor (ER)-negative (n=28) and it was 0.59 (95 % CI: 0.36-0.82) for ER-positive cancers (n=37). ER status was not reported for one patient. Conclusions: Our results indicate that the cell line derived 291-probeset genomic predictor of response to FEC/TX combination chemotherapy shows good performance in a blinded validation study, particularly in ER-negative patients.